Zymeworks To Cut Its Workforce By Almost 25%, Outlines 2022 & 2023 Priorities

Zymeworks Inc ZYME said that in conjunction with the renewed focus on key priorities and cost-efficiency, ten members (or 50%) of the former senior management team would be leaving the Company. 

  • Additionally, in line with these reductions in the senior management team, a Company-wide decrease in the workforce will be initiated with a target of reducing employee headcount by at least 25% by the end of 2022.
  • The Company held cash, cash equivalents, and short-term investments of approximately $250 million as of December 31, 2021. 
  • It reiterated its guidance on a financial runway to fund current operations through at least late 2022.
  • For 2022 and 2023, Zymeworks will prioritize the completion of recruitment in HERIZON-BTC-01 and HERIZON-GEA-01 studies of zanidatamab by mid-2022 and the end of 2023, respectively.
  • Related: Zymeworks' Zanidatamab Aces Mid-Stage Esophageal Cancer Trial.
  • The Company will also finalize a clear clinical development path for ZW49 based on additional clinical data expected in 2022 from the Phase 1 trial.
  • Zymeworks plans to select and advance two new antibody-drug conjugate or multispecific product candidates leveraging Zymeworks' therapeutic platforms to IND-enabling studies. 
  • It plans to submit related IND applications by the end of 2024.
  • Price Action: ZYME shares closed at $13.46  on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!